Business Wire

New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes


Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olodaterol in improving symptoms and lung function as well as patients’ satisfaction when inhaling from and handling the tiotropium/olodaterol soft-mist inhaler.1,2,3,4 The results of these studies reinforce the importance of patient needs and preferences as well as patients’ ability to properly inhale when prescribing inhaler therapy for COPD management.

“The importance of matching a specific inhaled therapy with patients’ personal needs and preferences cannot be overstated in COPD management,” said Prof Paola Rogliani, Head of Clinical Respiratory Unit, Policlinico Tor Vergata, Rome, Italy. “A novel bidimensional, pooled analysis enabled us to directly compare six LAMA/LABA fixed-dose combinations and demonstrate that tiotropium/olodaterol improved patient outcomes more than the other treatments in the class. Varying efficacy and safety of combinations in the same class should be considered for a patient-centred approach in COPD.”

Data presented at ERS reinforces the benefits of tiotropium/olodaterol LAMA/LABA* therapy in improving patient outcomes, specifically:1,4

- A pooled analysis exploring the effect of step-up COPD treatment from tiotropium at baseline to tiotropium/olodaterol,4 showed that optimising bronchodilation with tiotropium/olodaterol led to clinically relevant improvements in lung function, health status and breathlessness.4
- A bidimensional comparative analysis looked at the efficacy and safety profile of six LAMA/LABA fixed-dose combinations and found tiotropium/olodaterol surpassed all others in-class in terms of efficacy, while also having fewer cardiovascular serious adverse events.1

Further data presented reinforce satisfaction, inhaleability and ease of use associated with the tiotropium/olodaterol inhaler:2,3

- An open-label, observational study evaluating patients’ general condition as well as treatment and device satisfaction in COPD patients treated with tiotropium/olodaterol, found improved general condition as well as high satisfaction with handling and inhaling from the tiotropium/olodaterol device as reported by patients.2
- To guide the development of an enhanced tiotropium/olodaterol inhaler, two formative studies evaluating COPD patients’ general handling of the tiotropium/olodaterol and the tiotropium/olodaterol re-usable inhalers confirmed that a patient-centric design led to an enhanced tiotropium/olodaterol re-usable inhaler with improved usability and easier-to-read dose indicator.3

These findings are significant because in addition to the importance of individualising treatment, the internationally-recognised GOLD guidance document emphasises considering patient preferences and ability to use their inhaler when prescribing a specific COPD therapy.5 Studies suggest that up to 52% of COPD patients struggle to inhale from their device (including those with mild disease),6,7 and the ability to properly inhale medication plays a key role in COPD management.8,9

“As a company, we have been developing therapies and inhaler devices for people with respiratory conditions for almost a century,” said Dr Alberto de la Hoz, Global Head of Medical Affairs, Respiratory Franchise at Boehringer Ingelheim. “The data presented at ERS underscore the efficacy of tiotropium/olodaterol as a treatment for COPD patients with different clinical characteristics and needs, and how the Respimat® re-usable was enhanced based on HCP and patient feedback, addressing their evolving needs and preferences.”

Boehringer Ingelheim will present data from 11 abstracts relating to the COPD portfolio, host two scientific symposia and post daily podcasts featuring leading respiratory experts throughout the ERS Congress. To find out more, visit the Boehringer Ingelheim ERS webpage:

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit:

* Long-acting muscarinic antagonists/long-acting beta2 agonists
Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy for the Diagnosis, Management, and Prevention of COPD

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Julia Gußmann
Boehringer Ingelheim
Phone: +49 (6132) 77-171244
Fax: +49 (6132) 72-171244

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF to Webcast Fireside Chat at Stifel Virtual Cross Sector Insight Conference June 82.6.2020 22:15:00 CESTPress release

Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced that the Company’s management will be participating in a fireside chat at the Stifel Virtual Cross Sector Insight Conference on Monday, June 8, 2020 at 4:00 PM ET. Investors may access the live webcast on the Company's website at For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at, Twitter , Facebook, Instagram, and LinkedIn. View source version on information Micha

ZOOM International to Begin Doing Business As Elevēo2.6.2020 16:00:00 CESTPress release

ZOOM International a worldwide leader in omni-channel compliance recording, workforce optimization (WFO), and revenue protection software for contact centers will begin doing business solely as elevēo beginning June 2nd, 2020. This press release features multimedia. View the full release here: For over 20 years, ZOOM International has been a leading workforce optimization software provider in the contact center industry. Very early on, we were approached to solve a compliance problem with call recording. We built a creative software solution in record time, and began a journey crossing continents, employing hundreds of colleagues, and eventually improving operations, compliance, and customer experience for thousands of customers in 94 countries via more than 550 channel partners in the communications industry. Over time we have earned an 88 NPS score from ZOOM International customers & partners for our world-class support and in

Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its Newly Formed Medical Strategy Advisory Board2.6.2020 16:00:00 CESTPress release

DRE is pleased to welcome Joe Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its newly formed Medical Strategy Advisory Board (MSAB). These enhancements to the Company reflect the expanded need for keen guidance in this unprecedented time of convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes. Boystak is an experienced healthcare venture capitalist and senior healthcare investment banker having been Founding Managing Partner at Health2047 Capital Partners and Founding Managing Director, Global Life Sciences at Jefferies. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts fro

Andersen Global Expands Presence in Qatar2.6.2020 15:30:00 CESTPress release

Andersen Global announced its collaboration with Doha-based tax firm MS Partner, adding depth to the organization’s presence in Qatar and expanding its global platform. MS Partner was founded in 2018 and includes two Partners and more than 10 professionals that specialize in providing tax services to a variety of international clients including individuals and companies – both private and public. MS Partner’s Chairman His Excellency Shaikh Sultan Bin Jassim Bin Mohammed Al Thani is a prominent business leader in the State of Qatar. “We value our clients and people, and maintain the highest of professional standards,” said Office Managing Director Manikandan Rajan. “We’ve watched Andersen Global grow regionally as well as globally, and the organization has set the standard for providing clients with best-in-class service in an independent and seamless manner. We look forward to working closely with our fellow collaborating firm in Doha, Al-Khalifa Law, as well as all the collaborating f

Pegasus Development AG: Pegasus Present Its New Brand Pegastril - Nuevo2.6.2020 15:06:00 CESTPress release

The coronavirus pandemic harbours the potential for enormous growth in specific industries. To that end, however, it's important to identify which markets will be dominant in the future. One of the key growth sectors is the production and distribution of disinfectants and associated technologies. Regardless of whether a cure for, or vaccine against, COVID-19 is developed, protection against viruses and bacteria has become incredibly important across the globe and will continue to be a concern going forward. This was one of the reasons why Pegasus Development AG decided to partner with the British disinfectant manufacturer Nuevo. One of the decisive factors choosing Nuevo was its highly competitive product, which is free from alcohol, animal products, perfume, essential oils or dyes. Furthermore, the product has already been tested according to the highest stipulations of the European standard EN 1276, is manufactured according to the latest regulations of the European Biocides Directiv

PVH Corp. Announces Leadership Update at Tommy Hilfiger and PVH Europe2.6.2020 15:00:00 CESTPress release

PVH Corp. (NYSE:PVH), owner of a portfolio of iconic brands including TOMMY HILFIGER and CALVIN KLEIN, announced today that Daniel Grieder is stepping down from his role of Chief Executive Officer, Tommy Hilfiger Global & PVH Europe after 23 years in various management roles within the organization, and will be leaving the company to pursue other interests. Martijn Hagman will succeed Grieder and become the new Chief Executive Officer, Tommy Hilfiger Global & PVH Europe, effective June 2, 2020. Hagman is currently Chief Operating Officer, Tommy Hilfiger Global & PVH Europe and Chief Financial Officer, Tommy Hilfiger Global, overseeing operations, finance, digital business transformation, technology, business development and the Tommy Hilfiger global sustainability program. He is a 12-year veteran of the Tommy Hilfiger leadership team and has been instrumental in Tommy Hilfiger’s impressive global expansion and the strategy that has led to PVH Europe’s consistent year-over-year growth.